Single Versus Double Injection Costoclavicular Block
Study Details
Study Description
Brief Summary
In this trial, the objective is to compare single- and double-injection ultrasound-guided costoclavicular blocks. The rationale behind this idea is that a second local anesthetic injection, inside the costoclavicular space, may compensate for the dynamic cord dispersion seen with the single-injection technique. Thus the research hypothesis is that, compared to its single-injection counterpart, a double injection costoclavicular block will result in a shorter onset time.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The costoclavicular block (CCB) constitutes a relatively novel technique for infraclavicular brachial plexus blockade, whereby local anesthetics (LAs) are injected inside the costoclavicular space. In this location, the 3 cords of the brachial plexus are very tightly clustered together; this topography would theoretically result in a very swift brachial plexus block Unfortunately, in two recent trials comparing CCB and conventional infraclavicular brachial plexus block, the authors were unable to detect differences in success rate, onset times and LA requirement between the 2 methods. It could be speculated that the explanation resides in dynamic cord dispersion. With CCB, the initial needle target lies in the middle of the 3 cords of the brachial plexus. However, with LA injection, the cords can quickly migrate away from each other. Thus, the anatomical benefits conveyed by the initial compact topography may be lost.
In this trial, the objective is to compare single- and double-injection ultrasound-guided costoclavicular blocks. The rationale behind this idea is that a second local anesthetic injection, inside the costoclavicular space, may compensate for the dynamic cord dispersion seen with the single-injection technique. Thus the research hypothesis is that, compared to its single-injection counterpart, a double injection costoclavicular block will result in a shorter onset time.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Single Injection Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus |
Other: Single injection
Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
Drug: lidocaine, bupivacaine, epinephrine, dexamethasone
lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
|
| Experimental: Double Injection Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord. |
Other: Double injection
Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
Drug: lidocaine, bupivacaine, epinephrine, dexamethasone
lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
|
Outcome Measures
Primary Outcome Measures
- Onset time of brachial plexus blockade [Within 30 minutes of block performance]
Onset until a minimal composite score of 14 points in a scale of 0-16 points, evaluating sensitive and motor function of each 4 terminal branches.
Secondary Outcome Measures
- Performance time during the brachial plexus block [Intraoperative (During block performance)]
the sum of: 1. the acquisition time of the sonographic image and 2. the time to perform block itself (from skin anesthesia to the end of LA injection)
- Number of needle passes [Intraoperative (During block performance)]
The initial needle insertion counted as the first pass. Any subsequent needle advancement that is preceded by a retraction of at least 10 mm counts as an additional pass
- Procedure pain during the brachial plexus block [Intraoperative (During block performance)]
Pain reported during procedure, rated acording to a visual rating scale from 0 to 10 points (0= no pain and 10= worst imaginable pain)
- Incidence of surgical anesthesia [Thirty minutes after block performance]
Incidence of surgeries performed without the supplemental use of local anesthetics infiltration, narcotics or general anesthesia
- Incidence of Adverse events [Intraoperative (During block performance)]
Incidence of adverse events related to brachial plexus block ((paresthesia, vascular puncture, hematoma, Horner syndrome, pneumothorax)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
age between 18 and 75 years
-
American Society of Anesthesiologists classification 1-3
-
body mass index between 18 and 30
Exclusion Criteria:
-
adults who are unable to give their own consent
-
pre-existing neuropathy (assessed by history and physical examination)
-
coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or partial thromboplastin time ≥ 50)
-
renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)
-
hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)
-
allergy to local anesthetic
-
pregnancy
-
prior surgery in the infraclavicular costoclavicular region
-
chronic pain syndromes requiring opioid intake at home
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Montreal General Hospital | Montreal | Quebec | Canada | H3G-1A4 |
Sponsors and Collaborators
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- University of Chile
Investigators
- Principal Investigator: De Q Tran, MD, FRCPC, McGill University Health Centre/Research Institute of the McGill University Health Centre
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MUHC 2019-4673